Botulinum toxin type A versus botulinum toxin type B for cervical dystonia

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 10, 2016, Pages

  Duarte, Gonçalo S ^a,b   Castelão, Mafalda ^a,b   Rodrigues, Filipe B ^a,b   Marques, Raquel E ^a,b   Ferreira, Joaquim ^a,b   Sampaio, Cristina ^c   Moore, Austen P ^d   Costa, João ^a,b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^d THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; MUSCLE RELAXANT AGENT;

CERVICAL DYSTONIA; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; HUMAN; INJECTION SITE PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; SORE THROAT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; XEROSTOMIA; DYSTONIA; TORTICOLLIS;

BOTULINUM TOXINS, TYPE A; DYSTONIA; HUMANS; NEUROMUSCULAR AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TORTICOLLIS;

EID: 84992457835     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004314.pub3     Document Type: Review

References (86)

1. Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005;65:1423-9. [4393336; DOI: 10.1212/01.wnl.0000183055.81056.5c]
2. Pappert EJ, Germanson T. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized double-blind, noninferiority trial. Movement Disorders 2008;23:510-7. [4393337]
3. Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology 2005;65:765-7. [4393338]
4. Abrams KR, Gillies CL, Lambert PC. Meta-analysis of heterogeneously reported trials assessing change from baseline. Statistics in Medicine 2005;24:3823-44.
5. Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders 2013;28(7):863-73.
6. Altman DG, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Medical Research Methodology 2002;2(1):3.
7. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde effects of botulinum neurotoxin. Journal of Neuroscience 2008;28:3689-96.
8. Balint B, Bhatia KP. Isolated and combined dystonia syndromes - an update on new genes and their phenotypes. European Journal of Neurology 2015;22(4):610-7.
9. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6.
10. Benecke R. Clinical Relevance of Botulinum Toxin Immunogenicity. BioDrugs 2012;26(2):e1-e9.
11. Bentivoglio AR, Del Grande A, Petracca M, Tamara Ialongo T, Ricciardi L. Clinical differences between botulinum neurotoxin type A and B. Toxicon 2015;107:77-84. [DOI: http://dx.doi.org/10.1016/j.toxicon.2015.08.001]
12. British National Formulary. Botulinum toxin type A. National Institute for Health and Care Excellence May 2016. [http://www.evidence.nhs.uk/formulary/bnf/current/4-central-nervous-system/49-drugs-used-in-parkinsonism-and-related-disorders/493-drugs-used-in-essential-tremor-chorea-tics-and-related-disorders/torsion-dystonias-and-other-involuntary-movements/botulinum-toxin-type-a]
13. British National Formulary. Botulinum toxin type B. National Institute for Health and Care Excellence May 2016. [http://www.evidence.nhs.uk/formulary/bnf/current/4-central-nervous-system/49-drugs-used-in-parkinsonism-and-related-disorders/493-drugs-used-in-essential-tremor-chorea-tics-and-related-disorders/torsion-dystonias-and-other-involuntary-movements/botulinum-toxin-type-b]
14. Boroff DA, Chen GS. On the question of permeability of the blood-brain barrier to botulinum toxin. International Archives of Allergy and Applied Immunology 1975;48:495-504.
15. Brashear A. Botulinum toxin serotype A for cervical dystonia-an assessment. US Neurology 2008;4(2):58-61.
16. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M, CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Movement Disorders 2008;23(10):1353-60.
17. Broz˙ek JL, Guyatt GH, Schünemann HJ. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure. Health and Quality of Life Outcomes 2006;4:69.
18. Carpenter J, Kenward M. Multiple Imputation and its Application. Wiley, 2013.
19. Chan J, Brin MF, Fanh S. Idiopathic cervical dystonia: clinical characteristics. Movement Disorders 1991;6:119-26.
20. Cohen J. Statistical Power Analysis in the Behavioral Sciences. 2nd Edition. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc, 1988.
21. Comella CL, Fox SH, Bhatia KP, Perlmutter JS, Jinnah HA, Zurowski M, et al. Development of the comprehensive Cervical Dystonia Rating Scale: methodology. Movement Disorders 2015;2(2):135-41.
22. Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M editor(s). Therapy with Botulinum Toxin. New York (NY): Marcel Dekker, Inc, 1994:211-37.
23. Corbett MS, Higgins JP, Woolacott NF. Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool. Research Synthesis Methods 2014;5(1):79-85.
24. Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD003633.pub2; PUBMED: 15674910]
25. Cullis PA, Barnes M, Duane D, Chen RE, Freeman A, Fross R, et al. Safety and tolerability of repeated doses of Neurobloc (Botulinum toxin type B) in patients with cervical dystonia: an open-label, dose-escalation study. Movement Disorders 2000;15 (Suppl 2):29.
26. de Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proceedings of the National Academy of Sciences of the United States of America 1999;96:3200-5.
27. Defazio G, Jankovic J, Giel JL, Papapetropoulos S. Descriptive epidemiology of cervical dystonia. Tremor and Other Hyperkinetic Movements 2013;3:tre-03-193-4374-2.
28. Duchen LW. An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse. Journal of the Neurological Sciences 1971;14:47-60.
29. Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neuroscience Letters 1997;224(2):91-4.
30. Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group. A prevalence study of primary dystonia in eight European countries. Journal of Neurology 2000;247:787-92.
31. Fabbri M, Leodori G, Fernandes RM, Bhidayasiri R, Marti MJ, Colosimo C, et al. Neutralizing antibody and botulinum toxin therapy: a systematic review and meta-analysis. Neurotoxicity Research 2015;29:105-17. [PUBMED: 26467676]
32. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Oto-laryngologica 1993;113:400-4.
33. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology 1992;45:769-73.
34. Foltz EL, Knopp LM, Ward AA. Experimental spasmodic torticollis. Journal of Neurosurgery 1959;16:55-72.
35. Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?. Biologics: Targets & Therapy 2010 Dec;4:325-32.
36. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7-10.
37. GRADE Working Group, McMaster University. GRADEpro GDT. Version Date accessed: September 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
38. Greene PE, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Movement Disorders 1993;8(4):479-83.
39. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93.
40. Hallett M. The neurophysiology of dystonia. Archives of Neurology 1998;55(5):601-3.
41. Hanna PA, Jankovic J. Mouse bioassay versus western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 1998;50(6):1624-9.
42. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. Academic Press, Inc, 1985.
43. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
44. Higgins JP, Deeks JJ editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
45. Higgins JPT, Altman DG, Sterne JAC editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
46. Higgins JPT, Deeks JJ, Altman DG editor(s). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
47. Holland RL, Brown MC. Nerve growth in botulinum toxin poisoned muscles. Neuroscience 1981;6:1167-79.
48. Imberger G, Thorlund K, Gluud C, Wetterslev J. False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review. BMJ Open 2016;6(8):e011890.
49. Jahnanshani M, Marion M-H, Marsden CD. Natural history of adult-onset idiopathic torticollis. Archives of Neurology 1990;47:548-52.
50. Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology 2014;14(1):120.
51. Jankovic J. Botulinum toxin in clinical practice. Journal of Neurology, Neurosurgery, and Psychiatry 2004;75(7):951-7.
52. Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism & Related Disorders October 2007;13(7):411-6.
53. Juzans P, Comella J, Molgo J, Faille L, Angaut-Petit D. Nerve terminal sprouting in botulinum type-A treated mouse levator auris longus muscle. Neuromuscular Disorders 1996;6(3):177-85.
54. Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?. Clinical Neuropharmacology 2009;32(4):213-8.
55. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Medicine 2009;6:e1000100.
56. Macefield RC, Jacobs M, Korfage IJ, Nicklin J, Whistance RN, Brookes ST, et al. Developing core outcomes sets: methods for identifying and including patient-reported outcomes (PROs). Trials 2014;15:49.
57. Marques RE, Duarte GS, Rodrigues FB, Castelão M, Ferreira J, Sampaio C, et al. Botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews 2016, Issue 5. [DOI: 10.1002/14651858.CD004315.pub3; PUBMED: 27176573]
58. Matak I, Lacković Z. Botulinum toxin A, brain and pain. Progress in Neurobiology 2014;119-20:39-59.
59. Matak I, Lacković Z. Botulinum neurotoxin type A: actions beyond SNAP-25?. Toxicology 2015;335:79-84.
60. Michiels S, Piedbois P, Burdett S, Syz N, Stewart L, Pignon JP. Meta-analysis when only the median survival times are known: a comparison with individual patient data results. International Journal of Technology Assessment in Health Care 2005;21(1):119-25.
61. Müller K, Mix E, Adib Saberi F, Dressler D, Benecke R. Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. Journal of Neural Transmission 2009;116(5):579-85.
62. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
63. Palomar FJ, Mir P. Neurophysiological changes after intramuscular injection of botulinum toxin. Clinical Neurophysiology 2012;123(1):54-60.
64. Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 1999;354:259-68.
65. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006;295(6):676-80.
66. The Nordic Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Centre, The Cochrane Collaboration, 2014.
67. Rosales RL, Arimura K, Takenaka S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle & Nerve 1996;19:488-96.
68. Rosales RL, Dressler D. On muscle spindles, dystonia and botulinum toxin. European Journal of Neurology 2010;17:71-80.
69. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Statistics in Medicine 1991;10:585-98.
70. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
71. Simpson LL. Identification of the major steps in botulinum toxin action. Annual Review of Pharmacology and Toxicology 2004;44:167-93.
72. Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analysis - sometimes informative, usually misleading. BMJ 1999;318(7197):1548-51.
73. StataCorp Stata Statistical Software: release 14. Version Date accessed: September 2016. StataCorp, 2015.
74. Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T. The prevalence of primary dystonia: a systematic review and meta-analysis. Movement Disorders 2012;27(14):1789-96.
75. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. Journal of Clinical Epidemiology 2001;54(10):1046-55.
76. Sterne JAC, Egger M, Moher D editor(s). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
77. Tarsy D, Simon D. Dystonia. New Egyptian Journal of Medicine 2006;355:818-29.
78. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for trial sequential analysis (TSA). ctu.dk/tsa/files/tsamanual.pdf 2011.
79. Copenhagen Trial Unit. Trial Sequential Analysis. Version 0.9 Beta. Version Date accessed: September 2016. Copenhagen: Copenhagen Trial Unit, 2011.
80. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 2007;8:38.
81. Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. Journal of Clinical and Aesthetic Dermatology 2014;7(2):31-9.
82. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61:64-75.
83. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86.
84. Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ. A systematic review identifies a lack of standardization in methods for handling missing variance data. Journal of Clinical Epidemiology 2006;59(4):342-53.
85. Zoons E, Dijkgraaf MG, Dijk JM, van Schaik IN, Tijssen MA. Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value. Neurology 2012;259(12):2519-26.
86. Costa J, Borges AA, Espírito-Santo CC, Ferreira J, Coelho MM, Moore P, Sampaio C. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD004314.pub2]